The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint blockade, particularly anti-PD-L1 therapy, shows promise in various cancers.
• Optimizing response rates for anti-PD-L1 therapy in triple-negative breast cancer requires understanding PD-L1 regulation.

Purpose of the Study:

• To identify novel regulators of programmed death-ligand 1 (PD-L1) stability and expression.
• To investigate the role of endoplasmic reticulum (ER) stress in PD-L1 regulation.
• To explore the therapeutic potential of targeting PD-L1 regulatory pathways in triple-negative breast cancer.

Main Methods:

• Protein-protein interaction studies to identify binding partners of PD-L1.
• Endoplasmic reticulum (ER) stress induction and assessment of PD-L1 levels.
• Correlation analysis of GRP78 and PD-L1 expression with patient survival data.

Main Results:

• Glucose regulatory protein 78 (GRP78) was identified as a novel binding partner of PD-L1.
• GRP78 interacts with PD-L1 in the ER, enhancing PD-L1 stability and levels.
• ER stress induces PD-L1 in a GRP78-dependent manner.
• Dual high GRP78 and PD-L1 levels correlate with poor relapse-free survival in triple-negative breast cancer.

Conclusions:

• GRP78 is a novel regulator of PD-L1 stability and expression, particularly under ER stress conditions.
• The GRP78-PD-L1 interaction offers a new therapeutic target to potentially improve anti-tumor immunity.
• Targeting GRP78 may enhance the efficacy of anti-PD-L1 therapies in triple-negative breast cancer.